

X-13199

-3-

Remarks

Claims 1-12 are pending. Claims 4-7 are withdrawn. Claims 1-3, 9, and 11-12 have been canceled.

Claims 8 and 10 have been amended to limit administration to parenteral administration at a dose of 1 ug/kg/day to 10 mg/kg/day. Support for these amendments can be found, for example, at page 12 of the specification.

New claims 13-16 depend from claims 8 and 10. Support for claims 13-16 can be found, for example, at page 12 of the specification. Support for new claims 17-18 can be found, for example, at page 13 of the specification. No new matter has been added by any of these amendments. Applicants request entry.

Rejection of Claims 1-3, 9 and 11 under 35 USC Section 112

Claims 1-3, 9 and 11 were rejected under 35 USC Section 112, first paragraph, allegedly for non-enablement. Without conceding the basis for this rejection, Applicants have canceled these claims while reserving the right to later claims this subject matter thereby rendering the rejection moot. Applicants respectfully request withdrawal of this aspect of the rejection.

Rejection of Claims 1-3, and 12 under 35 USC Section 102(b)

Claims 1-3, and 12 were rejected under 35 USC Section 102(b), allegedly as being anticipated by US Patent Application Publication 2002/0065210 (hereinafter "Ashkenazi"). Without conceding the basis for this aspect of the rejection, Applicants have canceled claims 1-3 and 12 thereby rendering the rejection moot. Applicants reserve the right to later claim this subject matter.

Applicants will address the rejection as to claims 8, 10 and new claims 13-18. Claims 8 and 10 and new claims 13-16, dependent therefrom, are directed at a method for treating chronic obstructive pulmonary disease (claim 10) and pulmonary fibrosis (claim 8) by administering a specific dose of FLINT. Ashkenazi does not disclose either of these aspects of the claimed invention. As such claims 8, 10, and 13-16 are not anticipated by Ashkenzai.

X-13199

-4-

New claims 17 and 18 are directed at methods for treating pulmonary fibrosis (claim 17) and chronic obstructive pulmonary disease (claim 18) by continuous infusion of FLINT at specific dose ranges. Ashkenazi does not teach each of the elements in these claims. As such Ashkenazi does not anticipate claims 17 and 18. Applicants respectfully request withdrawal of this basis of the rejection and passage of the claims to issuance.

Rejection of Claims 8-9 and 10-11 under 35 USC Section 103

Claims 8-9 were rejected for allegedly being obvious over Ashkenazi in view of Hagimoto et al. (hereinafter "Hagimoto"). Without conceding the basis for this rejection, Applicants have canceled claim 9 thereby rendering the rejection moot as to claim 9.

Prima facie obviousness over a combination of references requires motivation to combine the cited references [See e.g. MPEP §706.02(j)]. In this case, even if there were motivation to combine Ashkenazi and Hagimoto, the combined teaching would not suggest Applicants' claimed invention. These references alone or together do not suggest Applicants' claimed invention. In particular there is no suggestion as to the particular disease being treated nor the particular dose or dose range being claimed. As such, claim 8 would not be obvious over Ashkenazi, alone or in combination with Hagimoto.

Applicants will also address the rejection as to new claims 13-18. Neither Ashkenazi nor Hagimoto, alone or taken together, discloses or suggests the specific dose ranges claimed. As such new claims 13-18 would not be obvious over Ashkenazi, alone or in combination with Hagimoto. Applicants request withdrawal of this basis of the rejection.

Claims 10-11 were rejected for alleged obviousness over Ashkenazi in view of Yamamoto et al. (hereinafter "Yamamoto") and Hebestreit et al. (hereinafter "Hebestreit"). Without conceding the basis for this rejection, Applicants have canceled claim 11 thereby rendering the rejection moot as to claim 11.

Even if there were motivation to combine Ashkenazi with

X-13199


-5-

Yamamoto and Hebestreit, the combined teaching would not suggest Applicants' claimed invention. Taking these references alone or together would not suggest Applicants' claimed invention. In particular there is no suggestion in any of these references as to the particular dose or dose range being claimed. As such, claim 10 would not be obvious over Ashkenazi, alone or in combination with Yamamoto and Hebestreit.

Applicants will also address the rejection as to new claims 13-18. Neither Ashkenazi nor Yamamoto and Hebestreit, alone or taken together, discloses or suggests the specific dose ranges claimed. As such new claims 13-18 would not be obvious over Ashkenazi, alone or in combination with Yamamoto and Hebestreit. Applicants request withdrawal of this basis of the rejection.


Applicants submit they have successfully addressed each point of the rejection and respectfully request withdrawal of the rejection and passage of the case to issuance as soon as possible.

Respectfully submitted,



Thomas D. Webster
Attorney/Agent for Applicant(s)
Registration No. 39,872
Phone: 317-276-3334

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288



June 16, 2005

Please type a plus sign (+) inside this box → +

FEE TRANSMITTAL		Complete if Known																																																																																																									
		Serial No.	10/089984																																																																																																								
		Application Date	October 6, 2000																																																																																																								
		US Nat'l Entry Date (if applicable)	July 1, 2002																																																																																																								
		First Named Inventor	BUMOL Thomas Frank																																																																																																								
		Group Art Unit	1647																																																																																																								
		Examiner Name	GALVEZ, JAMES JASON																																																																																																								
		Conf. No.	3218																																																																																																								
		Attorney Docket Number	X13199																																																																																																								
METHOD OF PAYMENT (check one)																																																																																																											
<p>1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:</p> <p>Deposit Account Number: 05-0840</p> <p>Deposit Account Name: Eli Lilly and Company</p> <p><input checked="" type="checkbox"/> Charge Any Additional Fee Required Charge the Issue Fee Set in 37 CFR 1.18 at the time of allowance</p>																																																																																																											
<p>FEE CALCULATION (continued)</p> <p>3. ADDITIONAL FEES</p> <table border="1"> <thead> <tr> <th>Fee Code</th> <th>Large Entity Fee (\$)</th> <th>Large Entity Fee Description</th> <th>Fee Paid</th> </tr> </thead> <tbody> <tr> <td>1051</td> <td>130</td> <td>Surcharge-late filing fee or oath</td> <td></td> </tr> <tr> <td>1052</td> <td>50</td> <td>Surcharge-late provisional filing fee or cover sheet</td> <td></td> </tr> <tr> <td>1053</td> <td>130</td> <td>Non-English specification</td> <td></td> </tr> <tr> <td>1251</td> <td>120</td> <td>Extension for reply within first month</td> <td></td> </tr> <tr> <td>1252</td> <td>450</td> <td>Extension for reply within second month</td> <td>450.00</td> </tr> <tr> <td>1253</td> <td>1,020</td> <td>Extension for reply within third month</td> <td></td> </tr> <tr> <td>1254</td> <td>1,590</td> <td>Extension for reply within fourth month</td> <td></td> </tr> <tr> <td>1255</td> <td>2,160</td> <td>Extension for reply within fifth month</td> <td></td> </tr> <tr> <td>1401</td> <td>500</td> <td>Notice of Appeal</td> <td></td> </tr> <tr> <td>1402</td> <td>500</td> <td>Filing a brief in support of an appeal</td> <td></td> </tr> <tr> <td>1452</td> <td>500</td> <td>Petition to revive-unavoidable</td> <td></td> </tr> <tr> <td>1453</td> <td>1,800</td> <td>Petition to revive-unintentional</td> <td></td> </tr> <tr> <td>1502</td> <td>1,400</td> <td>Utility issue fee (or reissue)</td> <td></td> </tr> <tr> <td>122</td> <td>130</td> <td>Petitions to the Commissioner</td> <td></td> </tr> <tr> <td>1801</td> <td>790</td> <td>Request for Continued Examination (RCE)</td> <td></td> </tr> <tr> <td colspan="4">Other fee (specify)</td> </tr> <tr> <td colspan="4">Independent claims</td> </tr> <tr> <td>1201</td> <td>— - 20 =</td> <td>X 50 = \$</td> <td>Other fee (specify)</td> </tr> <tr> <td>1203</td> <td>Multiple Dependent Claim</td> <td>Yes or No (if yes)</td> <td>Other fee (specify)</td> </tr> <tr> <td>1081</td> <td colspan="2">Claims and Excess Length Fees Total length (spec + drawings) — - 100 = excess pages \$</td> <td>Other fee (specify)</td> </tr> <tr> <td colspan="4">No extra charge for first 100 pages. Must pay \$250 for each addl 50 pages (or fraction thereof).</td> </tr> <tr> <td colspan="2">SUBTOTAL (2) (\$0)</td> <td colspan="2">SUBTOTAL (3) (\$450)</td> </tr> <tr> <td colspan="3">SUBMITTED BY</td> <td>Complete (if applicable)</td> </tr> <tr> <td>Typed or Printed Name Signature</td> <td colspan="2">Thomas D. Webster <i>Thomas D. Webster</i></td> <td>Reg. Number 39,872</td> </tr> <tr> <td></td> <td>Date</td> <td colspan="2">6/16/05</td> </tr> </tbody></table>				Fee Code	Large Entity Fee (\$)	Large Entity Fee Description	Fee Paid	1051	130	Surcharge-late filing fee or oath		1052	50	Surcharge-late provisional filing fee or cover sheet		1053	130	Non-English specification		1251	120	Extension for reply within first month		1252	450	Extension for reply within second month	450.00	1253	1,020	Extension for reply within third month		1254	1,590	Extension for reply within fourth month		1255	2,160	Extension for reply within fifth month		1401	500	Notice of Appeal		1402	500	Filing a brief in support of an appeal		1452	500	Petition to revive-unavoidable		1453	1,800	Petition to revive-unintentional		1502	1,400	Utility issue fee (or reissue)		122	130	Petitions to the Commissioner		1801	790	Request for Continued Examination (RCE)		Other fee (specify)				Independent claims				1201	— - 20 =	X 50 = \$	Other fee (specify)	1203	Multiple Dependent Claim	Yes or No (if yes)	Other fee (specify)	1081	Claims and Excess Length Fees Total length (spec + drawings) — - 100 = excess pages \$		Other fee (specify)	No extra charge for first 100 pages. Must pay \$250 for each addl 50 pages (or fraction thereof).				SUBTOTAL (2) (\$0)		SUBTOTAL (3) (\$450)		SUBMITTED BY			Complete (if applicable)	Typed or Printed Name Signature	Thomas D. Webster <i>Thomas D. Webster</i>		Reg. Number 39,872		Date	6/16/05	
Fee Code	Large Entity Fee (\$)	Large Entity Fee Description	Fee Paid																																																																																																								
1051	130	Surcharge-late filing fee or oath																																																																																																									
1052	50	Surcharge-late provisional filing fee or cover sheet																																																																																																									
1053	130	Non-English specification																																																																																																									
1251	120	Extension for reply within first month																																																																																																									
1252	450	Extension for reply within second month	450.00																																																																																																								
1253	1,020	Extension for reply within third month																																																																																																									
1254	1,590	Extension for reply within fourth month																																																																																																									
1255	2,160	Extension for reply within fifth month																																																																																																									
1401	500	Notice of Appeal																																																																																																									
1402	500	Filing a brief in support of an appeal																																																																																																									
1452	500	Petition to revive-unavoidable																																																																																																									
1453	1,800	Petition to revive-unintentional																																																																																																									
1502	1,400	Utility issue fee (or reissue)																																																																																																									
122	130	Petitions to the Commissioner																																																																																																									
1801	790	Request for Continued Examination (RCE)																																																																																																									
Other fee (specify)																																																																																																											
Independent claims																																																																																																											
1201	— - 20 =	X 50 = \$	Other fee (specify)																																																																																																								
1203	Multiple Dependent Claim	Yes or No (if yes)	Other fee (specify)																																																																																																								
1081	Claims and Excess Length Fees Total length (spec + drawings) — - 100 = excess pages \$		Other fee (specify)																																																																																																								
No extra charge for first 100 pages. Must pay \$250 for each addl 50 pages (or fraction thereof).																																																																																																											
SUBTOTAL (2) (\$0)		SUBTOTAL (3) (\$450)																																																																																																									
SUBMITTED BY			Complete (if applicable)																																																																																																								
Typed or Printed Name Signature	Thomas D. Webster <i>Thomas D. Webster</i>		Reg. Number 39,872																																																																																																								
	Date	6/16/05																																																																																																									